Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livmoniplimab + Budigalimab in mUC
NCT06632951Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of livmoniplimab in urothelial carcinoma (UC) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Overall Survival at 3.5 years. Started Jan 2025; status: active, not recruiting.
02
Drugs
livmoniplimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06632951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632951.